期刊文献+

养血清脑颗粒+西比灵在偏头痛患者中的应用及安全性研究 被引量:3

下载PDF
导出
摘要 目的:分析养血清脑颗粒+西比灵对偏头痛病人实施治疗的临床效果以及安全性。方法:将我院2014年2月-2017年2月收治的偏头痛病人58例随机分成对照组(n=29)与治疗组(n=29)。对照组接受比西灵治疗,而治疗组接受西比灵结合养血清脑颗粒治疗,比较治疗前后的疼痛、生活质量、临床治疗效果以及不良反应。结果:除两组不良反应没有差异外,在疼痛、生活质量、临床治疗效果方面,治疗组均优于对照组(P均<0.05)。结论:养血清脑颗粒+西比灵用于偏头痛患者临床疗效显著,提升患者生活质量。 Objective:analysis to raise for migraine patients serum brain granule + sibeline implementing clinical effect and safety of treatment. Methods:from February 2014 to February 2017 were 58 cases of migraine patients randomly divided into control group(n = 29) and treatment group(n = 29). Control group than the west spirit therapy, combined with the raise of serum and the treatment group accepted sibeline brain treatment, compared before and after treatment of pain, quality of life, clinical treatment effect and adverse reactions. The results of Except there is no difference between two groups of adverse reactions, in pain, quality of life, clinical treatment, the treatment group were superior to the control group(P < 0.05). Conclusion:to raise serum brain particles used in migraine patients clinical curative effect is distinct + sibeline, improve patient quality of life.
出处 《中国妇幼健康研究》 2017年第S3期458-458,共1页 Chinese Journal of Woman and Child Health Research
关键词 养血清脑颗粒 西比灵 偏头痛 安全性 临床效果 migraine security raised serum brain particles sibeline clinical effect
  • 相关文献

参考文献4

二级参考文献44

  • 1黄世杰,EdvinssonL.动物及人类实验性头痛模型[J].国外医学(药学分册),1995,22(4):228-231. 被引量:1
  • 2Diamond S,Bigal ME, Silberstein S, et al. Patterns of di- agnosis and acute and preventive treatment for migraine in the United States: results from the American Migaine Prevalence and Prevention study[J]. Headache, 2007,47 (3) :355-363.
  • 3Buse D, Manack A, Serrano D, et al. Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study[J]. Headache, 2012,52(1) :3-17.
  • 4Koppen H, Palm-Meinders I, Kruit M, et al. The impact of a migraine attack and its after-effects on perceptual or- ganization, attention, and working memorY[J]. Cephalalgi a,2011,31(11) : 1419-1427.
  • 5Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States,data from the A- merican Migaine studyII[J]. Headache, 2001,41 (7): 646-657.
  • 6Burton WN, Landy SH, Downs KE, et al. The impact of migraine and the effect of migraine treatment on work- place productivity in the United States and suggestions for future research[J]. Mayo Clin Proc, 2009, 84 (5) : 436-445.
  • 7Dahlof C, I.oder E,Diamond M, et al. The impact of mi- graine prevention on daily activities:a longitudinal and re sponder analysis from three topiramate placebo-controlled clinical trials[J]. Health Qual Life Outcomes, 2007,1 (5) : 56.
  • 8Benedek K,Tajti J, Vecsei L. Headache: diagnosis and treat- ment[J]. Orv Hetil,2006,147(37) : 1771-1776.
  • 9Park JW,Shin HE,Kim JS,et al. Assessing migraine dis- ability by diary-based measurement: relationship to the characteristics of individual headache attacks [J]. Eur J Neurol,2008,76(15) :817-821.
  • 10Ustan TB, Chatterji S, Kostanjsek N, et al. Developing the World Health Organization Disability Assessment Schedule 2.0[J]. Bull World Health Organ,2010,88(11) :815-823.

共引文献51

同被引文献82

引证文献3

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部